Host Defense Peptides And Their Potential As Therapeutic Agents

This book offers an overview of our current understanding of host defense peptides and their potential for clinical applications as well as some of the obstacles to this. The chapters, written by leading experts in the field, detail the number and diversity of host defense peptides, and discuss the therapeutic potential not only of antibacterial, but also of antifungal, antiviral, plant antimicrobial and anticancer host defense peptides. The authors provide new insights into their mechanisms of action and their immunomodulatory properties, and review recent advances in the design of novel therapeutic molecules. Lastly, their potential to prevent preterm births and Staphylococcus aureus infections is highlighted. The book is of interest to researchers, industry and clinicians alike.

Cationic antimicrobial peptides are multifunctional peptides of the innate immune system, which not only act directly against microorganisms, but also signal between early and late immune responses and modulate inflammatory reposnes. The significance of these host defence peptides in combating infection and in host-microbe homeostasis has become increasingly clear, through advances made by microbiologists, biochemists, biophysicists, immunologists, molecular biologists, and a range of medical and pharmaceutical researchers. This book, drawing together contributions from leading scientists, reviews significant recent advances in our knowledge of mammalian antimicrobial peptides. In addition to providing up-to-date overviews of their structure, expression and biology, their multiple activities and interactions with microbial populations as well as their potential application as novel therapeutic agents are summarized. Chapters describing developments using animal models and investigations of the roles of these host defence peptides in microbial infections are complemented by chapters addressing their mechanisms of action and of microbial resistance.

Antimicrobial peptides (AMPs) have attracted extensive research attention worldwide. Harnessing and creating AMPs synthetically has the potential to help overcome increasing antibiotic resistance in many pathogens. This new edition lays the foundations for studying AMPs, including a discovery timeline, terminology, nomenclature and classifications. It covers current advances in AMP research and examines state-of-the-art technologies such as bioinformatics, combinatorial libraries, high-throughput screening, database-guided identification, genomics and proteomics-based prediction, and structure-based design of AMPs. Thoroughly updated and revised, this second edition contains new content covering: defensins; cathelicidins; anti-MRSA, antifungal, antiviral, anticancer and antibiofilm strategies; combined treatments; adjuvants in vaccines; advances in AMP technologies that cover surface coating to prevent biofilm formation; nanofiber encapsulation technologies for delivery and sustained release; and understanding innate immunity and the basis for immune boosting to overcome obstacles in developing AMPs into therapeutic agents. Written and reviewed by a group of established investigators in the field, Antimicrobial Peptides is a valuable resource for postgraduate students, researchers, educators, and medical and industrial personnel.

The Yearbook compiles the most recent developments in experimental and clinical research and practice in one comprehensive reference book. The chapters are written by well recognized experts in the field of intensive care and emergency medicine. It is addressed to everyone involved in internal medicine, anesthesia, surgery, pediatrics, intensive care and emergency medicine.

Human coronaviruses caused the SARS epidemic that infected more than 8000 people, killing about ten percent of them in 32 countries. This book provides essential information on these viruses and the development of vaccines to control coronavirus infections.

Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.

This book deals with the emerging concept that certain pathogenic bacteria and viruses, when infecting people with cancer, actively fight tumors, allowing their regression. Although such observations go back more than 100 years, use of specific bacterial strains, or viruses, usually genetically modified with known anticancer drugs, and their protein/peptide products, has gained ground in recent years, allowing significant cancer regression in clinical trials with stage III/IV cancer patients or even in pediatric brain tumor patients, often without any demonstration of toxicity. It is composed of 12 chapters written by pioneers in microbial, biotech, and cancer research and covers the emerging roles of various microorganisms and their products in cancer therapy. The book highlights the benefits of using conventional cancer treatments (such as chemo- and radiotherapies) with microbial-based therapies. Such combinatorial therapies have gained particular attention as a strategy to overcome drug resistance, and the readers of the book will discover their impact on fundamental research and promising results from clinical trials.